Sign in

PPBT on Nasdaq

Kitov Pharma

Kitov Pharma is a Clinical stage biopharmaceutical company based in Tel Aviv, founded in 1968.1 Its shares trade on Nasdaq under the symbol PPBT.1

Price unavailable

Last updated Oct 21, 2026.

Overview

-$26.5MNet income, fiscal 20253
1968Founded1

Compare with Galena Biopharma, Shattuck Labs, Inc. or 60 DEGREES PHARMACEUTICALS, INC., or pick any stock.

  • TickerPPBT on Nasdaq1
  • Industrybiopharmaceutical1
  • Headquartersתל אביב-יפו1
  • Legal formpublic company1
  • Listed onTel Aviv Stock Exchange (KTOV), Nasdaq (KTOV)1
  • Incorporated inIsrael4
  • Business address4 Oppenheimer Street, Science Park, Rehovot, L3 76701044
  • Filer categoryNon-accelerated filer4

See how the biggest companies compare on our leaderboards

The Company is headquartered in Rehovot, Israel and our telephone number is +972-3-933-3121. Our website address is www.purple-biotech.com.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2020

-1261.2%Operating margin6
2870.1%Net margin7
0.0%Revenue growth, 20208
36.0%Return on equity9
$1.5MFree cash flow7

Where the money goes

Where each dollar of revenue went, fiscal 2020

  • Selling, general and admin17¢$6.0M
  • Profit83¢$28.7M

Out of $1.0M in revenue.87

Where each dollar of operating cash went, fiscal 2020

  • Capital spending9¢$156.0K
  • Kept or used elsewhere91¢$1.5M

Out of $1.7M of cash from operations.78

Financial statements

Revenue68$1.0M in 2020+0% since 2018
0$250.0K$500.0K$750.0K$1.0M2018: $1.0M$1.0M20182019: $1.0M$1.0M2019+0%2020: $1.0M$1.0M2020+0%
Operating income6-$12.6M in 2020+61% since 2018
-$15.0M-$10.0M-$5.0M02018: -$7.8M-$7.8M20182019: -$7.2M-$7.2M2019−9%2020: -$12.6M-$12.6M2020+76%
Net income67$28.7M in 2020+415% since 2018
0$10.0M$20.0M$30.0M2018: $5.6M$5.6M20182019: $5.4M$5.4M2019−3%2020: $28.7M$28.7M2020+431%

Every line of the income statement as filed: the last 3 fiscal years, latest first.3

Period ending2025-12-312024-12-312023-12-31
Research and development expenses$3.7M$7.6M$17.0M
General and administrative expenses$3.2M$3.2M$5.2M
Impairment loss$20.5M$202.0K
Operating loss$27.5M$11.0M$22.3M
Change in fair value of warrants-$1.5M-$3.3M-$3.5M
Finance expenses$982.0K$483.0K$2.2M
Finance income-$424.0K-$868.0K-$992.0K
Finance income, net-$966.0K-$3.7M-$2.3M
Loss for the year$26.5M$7.3M$20.0M
Loss (profit) from cash flow hedges$19.0K-$25.0K
Owners of the Company$26.4M$7.2M$19.9M
Non-controlling interests$106.0K$39.0K$97.0K
Owners of the Company$26.4M$7.3M$19.9M
Non-controlling interests$106.0K$39.0K$97.0K
Total comprehensive loss for the year$26.5M$7.3M$20.0M
Basic loss per Share USD (in Dollars per share)$0.03
Diluted loss per Share USD (in Dollars per share)$0.03
Number of ADSs used in calculation (in Shares)480.1K shares
Number of Shares used in calculation (in Shares)960.1M shares

Compare Kitov Pharma with another company

Corporate structure

Kitov Pharma sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Kitov Pharma

  • Kitov Pharma תל אביב-יפו

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Kitov Pharma reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$124.0K3 Dec 31, 2025$124.0K3 Dec 31, 20240%
Operating-lease assets (leased space)$222.0K3 Dec 31, 2025$164.0K3 Dec 31, 2024+35.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$8.7M3 Dec 31, 2025$7.4M3 Dec 31, 2024+17.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$7.4M3 Dec 31, 2025$27.8M3 Dec 31, 2024−73.6%

Leadership

Who has led Kitov Pharma, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Gil Efron2026–now
197019801990200020102020
Board members and other officers (5)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Vice President of Research and DevelopmentHadas Reuveni named Oct 31, 2023 to Jul 15, 202417
  • Vice President of OperationsIdo Morpurgo named Oct 31, 2023 to Jul 15, 202417
  • Chief Financial OfficerLior Fhima named Oct 31, 2023 to Jul 15, 202417
  • Chief Business OfficerFabien Sebille named Oct 31, 202318
  • Chairman of the Board of DirectorsEric Rowinsky named Oct 31, 2023 to Jul 15, 202417
  • DirectorIsaac Israel named Oct 31, 2023 to Jul 15, 202417
  • DirectorOri Hershkovitz named Oct 31, 2023 to Jul 15, 202417
  • DirectorYael Margolin named Jul 15, 202417

Former names

  • Kitov Pharma Ltd.Jan 25, 2018 to Dec 10, 20204
  • Kitov Pharmaceuticals Holdings Ltd.Aug 18, 2014 to Dec 21, 20174

Timeline

  1. Mar 31, 2026New chief executive Gil Efron becomes CEO11
  2. Nov 20, 2015Went public Listed on NASDAQ1
  3. 1968Founded Founded1

Calendar

Coming up

  1. Nov 13, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($2.90) a share, on Nov 14, 2025.19

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

217 filings to the SEC since October 2021: 5 annual reports, 8 insider forms, 10 large holders, 2 private raises, 192 other. The latest 20:

  1. Oct 5, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  2. Sep 9, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  3. Sep 2, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  4. Aug 14, 2026SCHEDULE 13G/A EDGAR
  5. Aug 10, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  6. Aug 7, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  7. Jul 29, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  8. Jun 23, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  9. Jun 11, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  10. May 20, 2026F-3 REGISTRATION STATEMENT EDGAR
  11. May 15, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  12. May 13, 2026SCHEDULE 13G/A EDGAR
  13. Apr 27, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  14. Apr 23, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  15. Apr 17, 20263 EDGAR
  16. Apr 7, 20263 EDGAR
  17. Apr 6, 20263 EDGAR
  18. Mar 31, 20263 EDGAR
  19. Mar 30, 20263/A EDGAR
  20. Mar 30, 20263 EDGAR

The 217 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$9.9M 2023–2024
Money received by yearMoney received by year, 2023–2024: $9.9M in all. Private raises (Form D) $9.9M.$0$2M$4M$6M2023 · Private raises (Form D): $5.4M20232024 · Private raises (Form D): $4.5M2024
Figures by year
YearPrivate raises (Form D)Total
2024$4.5M$4.5M
2023$5.4M$5.4M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Jul 1, 2024Raised $4.5 million in a private offering of securities17 Form D: 2 investors so far Form D
  2. Oct 17, 2023Raised $5.4 million in a private offering of securities18 Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
SmartHarvest Portfolios, LLC28,468$47.8K0.0%+10,341
Citadel Advisors LLC13,166$22.1K0.0%New
Susquehanna International Group, Llp12,847$21.6K0.0%−40,556
Independent Advisor Alliance11,901$20.0K0.0%New
Arax Advisory Partners1,453$2.4K0.0%New
Rhumbline Advisers856$1.4K0.0%+146
UBS Group AG751$1.3K0.0%+652
Morgan Stanley197$3310.0%−381
Hrt Financial LP14,640$240.0%New
Northwestern Mutual Wealth Management Co8$130.0%No change
IFG Advisory, LLC7$120.0%New
SBI Securities Co., Ltd.3$50.0%−28
Royal Bank Of Canada128$00.0%+118

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Kitov Pharma is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARPURPLE BIOTECH LTD.2
  • CIK0001614744
  • Filer statusNon-accelerated filer not an emerging growth company; not a shell company5
  • Incorporated inIsrael5
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address4 Oppenheimer Street, Science Park, Rehovot, L3 76701042
  • Phone972393331212
  • Shares outstanding1,858,911,801 shares as of Dec 31, 20255
  • AuditorSomekh Chaikin, Tel-Aviv, Israel PCAOB ID 1057; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceAug 18, 20142
  • Filings576 in all: 6-K (354), EFFECT (21), CORRESP (20), 424B3 (15), UPLOAD (15), SC 13G (14), D (13), 424B5 (12)2
    All 35 form types

    SC 13G/A (12), 20-F (11), F-3 (10), 6-K/A (9), F-1/A (9), 3 (7), F-1 (7), POS AM (7), S-8 (5), 424B4 (4), SCHEDULE 13G (4), SCHEDULE 13G/A (4), 20-F/A (3), DRS (3), AW (2), CT ORDER (2), F-1MEF (2), F-3/A (2), 25-NSE (1), 3/A (1), 8-A12B (1), CERTNAS (1), DRS/A (1), DRSLTR (1), F-6 (1), FWP (1), RW (1)

  • Latest filingsAnnual report (20-F) Mar 19, 2026

Securities registered for trading

ClassSymbolExchange
American Depositary Shares, each representing 2,000 Ordinary SharesPPBTNASDAQ

From the cover page of the 20-F filed Mar 19, 2026 (Section 12(b) of the Exchange Act).5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24